Nanjing Kingfriend Biochemical Pharmaceutical Co., Ltd (SHA: 603707), a Chinese pharmaceutical company, has announced the acquisition of Yusimry, a biosimilar of adalimumab, from U.S. firm Coherus Biosciences (NASDAQ: CHRS) for a purchase price of USD 40 million. This deal includes the marketing approval, patents, and related assets of the drug, which is listed in the United States.
Following the transaction, Kingfriend Bio will assume the role of the sole Marketing Authorization Holder (MAH) for Yusimry, a biosimilar version of AbbVie’s Humira (adalimumab), used for treating autoimmune diseases. As of the end of 2023, there are a total of 10 such adalimumab biosimilars available in the U.S. market, produced by companies including Amgen, Boehringer Ingelheim, Sandoz, Samsung Bioepis, Pfizer, Mylan, Coherus, Fresenius, Celltrion, and Alvotech.- Flcube.com
